0% Weight Loss per STEP Trials STEP trial studied FDA-approved Wegovy (semaglutide 2.4mg), not compounded semaglutide
Yes, orforglipron is an oral GLP-1 receptor agonist currently under development, showing promising results in clinical trials for glycemic control and weight loss
The court found these mistakes serious enough to warrant a new trial
Peptide therapy may be worth the cost for patients who want a medically guided approach to recovery, fat loss support, anti-aging, hormone optimization, injury repair, or improved overall wellness
If the medication causes side effects that make continuation difficult, that's a clinical conversation - not a refund pathway
Were grateful that there was a guy who tried to piece this thing together. If my trust is in question, I cant go after these bigger goals